menu
    • menu
    [{"orgOrder":0,"company":"Q BioMed","sponsor":"Clionix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Licensing Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q BioMed \/ Clionix","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Clionix"},{"orgOrder":0,"company":"Q BioMed","sponsor":"isoSolutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q BioMed \/ isoSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ isoSolutions"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Chengdu Syncor Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q BioMed \/ Chengdu Syncor Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Chengdu Syncor Pharmaceutical"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Uttroside B","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uttroside B","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Oklahoma Medical Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Uttroside B","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Oklahoma Medical Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Oklahoma Medical Research Foundation"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MAN-19","moa":"Tie2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Mannin Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MAN-19","moa":"Tie2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Mannin Research","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Mannin Research"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Mannin Research","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"MAN-01","moa":"Tie-2","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Solution","sponsorNew":"Q BioMed \/ Mannin Research","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Mannin Research"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Q BioMed \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Q BioMed

    Menu

    Q BioMed

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MAN-01

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Mannin Research

                            Deal Size : $42.3 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Q Biomed Announces Addition Of Multi-Million Dollar Asset Value With Equity Stake In Maniin Research Inc.

                            Details : By utilizing MRI’s internal pro-forma revenue projections for 2023 & 2024 and comparable market transactions, MRI’s drug development pipeline including MAN-01 and companion diagnostics, are estimated to achieve a net present value.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 14, 2022

                            Lead Product(s) : MAN-01

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Mannin Research

                            Deal Size : $42.3 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Uttroside B

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Oklahoma Medical Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q Biomed Announces Publication of Pre-clinical Research Showing Superior Safety and Efficacy Against Current F...

                            Details : Present study attests to previous report that Uttroside-B is pharmacologically safe up to five times IC50 dose in acute and sub-chronic toxicity models, while even IC50 dose of sorafenib is toxic to immunocompromised mice, and elevated doses of sorafenib...

                            Product Name : Uttroside-B

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2022

                            Lead Product(s) : Uttroside B

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Oklahoma Medical Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Uttroside B

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q Biomed Announces Publication of Research Showing Augmented Efficacy of Its Drug Candidate Uttroside-b Agains...

                            Details : In the initial Scientific Reports study, researchers showed that in animal models, Uttroside-B was ten times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the FDA for liver cancer approved at the time.

                            Product Name : Uttroside-B

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 16, 2022

                            Lead Product(s) : Uttroside B

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Chengdu Syncor Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market

                            Details : The agreement is expected to be a high-growth opportunity to supply Strontium89 in the Chinese market. Strontium89 is FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic...

                            Product Name : Metastron

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            March 07, 2022

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Chengdu Syncor Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MAN-19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Mannin Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 Therapeutic Program Hea...

                            Details : MAN-19 therapeutic is a recombinant fusion protein that treats the patient, instead of targeting the virus. It is not a cure for COVID, but it strengthens a patient's blood vessels and protects them against ARDS, breathing problems, sepsis and other infe...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 22, 2021

                            Lead Product(s) : MAN-19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Mannin Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : isoSolutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

                            Details : Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.

                            Product Name : Metastron

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            August 10, 2021

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : isoSolutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Clionix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Midd...

                            Details : Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait & Pakistan.

                            Product Name : Metastron

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            July 12, 2021

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Clionix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Uttroside B

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan

                            Details : The patent titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma” is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC).

                            Product Name : Uttroside-B

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 26, 2021

                            Lead Product(s) : Uttroside B

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MAN-19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program

                            Details : Human and genetic studies, as well as animal models of endothelial dysfunction collectively suggest that by targeting Tie2 receptor, MAN-19 may be effective in the treatment of a number of complications associated with viral infections such as COVID-19 a...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 26, 2020

                            Lead Product(s) : MAN-19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics

                            Details : The Joint venture will deploy Cyclica's unique AI platform to accelerate the development of new treatments based on Mannin's Tie2 based platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 22, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth